Verve Therapeutics’ $306 Million IPO

Wilson Sonsini Goodrich & Rosati advised Verve Therapeutics on the deal. Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here
  Share:
Martina Bellini

Author: Martina Bellini

…

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here